Shares of Vir Biotechnology, Inc. (VIR) tumbled 5.43% in pre-market trading on Thursday following the release of its disappointing first-quarter 2025 financial results. The biotechnology company reported a larger-than-expected loss and a significant revenue decline, raising concerns among investors about its financial health and future prospects.
Vir Biotechnology reported a quarterly adjusted loss of $0.88 per share, worse than the $0.84 loss per share analysts had predicted. This also marks a substantial decline from the $0.48 loss per share reported in the same quarter last year. More alarmingly, the company's revenue plummeted by 94.6% to just $3.03 million, falling far short of the $8.59 million Wall Street had anticipated. The dramatic revenue drop and widening losses resulted in a quarterly net loss of $120.97 million for the company.
The poor quarterly performance adds to Vir Biotechnology's recent struggles in the stock market. Prior to this earnings release, the company's shares had already fallen by 13.4% this quarter and lost 23.6% year-to-date. Despite these challenges, analysts maintain a generally positive outlook on the stock, with a consensus "buy" rating and a median 12-month price target of $20.00. However, investors appear to be reassessing the company's value in light of these latest results, as reflected in the sharp pre-market decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.